Athira Pharma Announces Upcoming Poster Presentation at American Academy of Neurology (AAN) 2024 Annual Meeting
Presentation to highlight therapeutic potential of Athira’s small molecules targeting the neurotrophic HGF system in neurodegenerative disorders, including Alzheimer’s disease, Parkinson’s disease and amyotrophic lateral sclerosis
BOTHELL, Wash., April 03, 2024 (GLOBE NEWSWIRE) -- Athira
Pharma, Inc. (NASDAQ: ATHA), a late clinical-stage biopharmaceutical company focused on developing novel small molecules to restore neuronal health and slow neurodegeneration, today announced a
planned poster presentation at the upcoming American Academy of Neurology (AAN) 2024 Annual Meeting, to be held April 13 – 18, 2024, in Denver, Colorado and online. The presentation will highlight
preclinical data supporting the continued development of Athira's pipeline of small molecule candidates targeting the neurotrophic hepatocyte growth factor (HGF) system, including fosgonimeton for
Alzheimer’s disease, ATH-1105 for amyotrophic lateral sclerosis (ALS), and ATH-1020 for Parkinson’s disease.
AAN 2024 Presentation Details:
Title: Targeting Neurotrophic HGF Signaling for the Treatment of Neurodegenerative Disorders
Session: Poster Session 11: General Neurology: Novel Concepts
Date/Time: Wednesday, April 17, 2024: 5:30 – 6:30 p.m. MDT
Presenter: Kevin Church, Ph.D., Chief Scientific Officer, Athira Pharma
The abstract is available on the AAN website here. The poster presentation will be available on the Scientific Publications & Presentations page of the company’s website at www.athira.com.
Athira’s drug development pipeline includes potential first-in-class (fosgonimeton) and next-generation (ATH-1105 and ATH-1020) small molecule drug candidates designed to promote the neurotrophic HGF system, which activates neuroprotective, neurotrophic and anti-inflammatory pathways in the nervous system. Athira’s drug candidates have distinct properties, which the company believes may be applicable to a broad range of neurodegenerative diseases.
About Fosgonimeton
Fosgonimeton is a potentially first-in-class, once daily, subcutaneously administered small molecule drug candidate. Targeting the protection and repair of neuronal networks, fosgonimeton has
disease-modifying potential to address a broad range of neurodegenerative diseases, including Alzheimer’s disease, Parkinson’s disease, and dementia with Lewy bodies.
Lesen Sie auch
About ATH-1105
ATH-1105 is a next-generation, orally administered, small molecule drug candidate in development for the potential treatment of ALS as the company’s initial indication. In preclinical models of
ALS, ATH-1105 has been shown to significantly increase survival, enhance motor and nerve function, reduce peripheral nerve demyelination and axon degeneration, and improve neurodegeneration and
inflammation.